SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: biowa who wrote (4738)4/23/1998 4:08:00 PM
From: Henry Niman  Read Replies (1) of 9719
 
biowa, As is fairly obvious from the size of LGND's pipeline, they are grossly under funded. In house they seem to be focused on rexinoids and androgen antagonists. Their partner for some of the progesterone analogs is AHP, who is more focused on the estrogen side (they have a $1 Billion Premarin market to protect). I'm not sure when progesterone analogs are slated to enter the clinic, but as can be seen from the table, many compounds should be just about finished with pre-clinical testing and are ready for IND filing.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News